Gilead Sciences (GILD) is trading up at $157.37 (+2.49%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Gilead Sciences revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $30.4B | $26.1B | $22.1B | $22.4B | $24.7B | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Growth (year over year) | −6.9% | −14.1% | −15.2% | +1.5% | +10.0% | +10.6% | −0.1% | −0.6% | +6.0% | +2.4% |
| Gross profit | $26.1B | $21.7B | $17.3B | $17.8B | $20.1B | $20.7B | $21.6B | $20.6B | $22.5B | $23.2B |
| Gross margin | 86.0% | 83.3% | 78.1% | 79.2% | 81.5% | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| Operating income | $17.6B | $14.1B | $8.20B | $4.29B | $4.07B | $9.92B | $7.33B | $7.61B | $1.66B | $10.0B |
| Operating margin | 58.0% | 54.1% | 37.1% | 19.1% | 16.5% | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Net income | $13.5B | $4.63B | $5.46B | $5.39B | $123.0M | $6.22B | $4.59B | $5.67B | $480.0M | $8.51B |
| Net margin | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| EPS (diluted) | $9.94 | $3.51 | $4.17 | $4.22 | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Balance sheet | ||||||||||
| Cash and equivalents | $8.23B | $7.59B | $17.9B | $11.6B | $6.00B | $5.34B | $5.41B | $6.08B | $9.99B | $7.56B |
| Total assets | $57.0B | $70.3B | $63.7B | $61.6B | $68.4B | $68.0B | $63.2B | $62.1B | $59.0B | $59.0B |
| Total liabilities | $37.6B | $49.8B | $42.1B | $39.0B | $50.2B | $46.9B | $42.0B | $39.4B | $39.7B | $36.4B |
| Long-term debt | $26.3B | $30.8B | $24.6B | $22.1B | $28.6B | $25.2B | $23.0B | $23.2B | $24.9B | $22.1B |
| Shareholders' equity | $18.9B | $20.4B | $21.4B | $22.5B | $18.2B | $21.1B | $21.2B | $22.8B | $19.3B | $22.7B |
| Cash flow | ||||||||||
| Operating cash flow | $17.0B | $11.9B | $8.40B | $9.14B | $8.17B | $11.4B | $9.07B | $8.01B | $10.8B | $10.0B |
| Capital expenditure | $748.0M | $590.0M | $924.0M | $825.0M | $650.0M | $579.0M | $728.0M | $585.0M | $523.0M | $563.0M |
| Free cash flow | $16.3B | $11.3B | $7.48B | $8.32B | $7.52B | $10.8B | $8.34B | $7.42B | $10.3B | $9.46B |
| Dividends paid | $2.46B | $2.73B | $2.97B | $3.22B | $3.45B | $3.60B | $3.71B | $3.81B | $3.92B | $4.00B |
| Share buybacks | $11.0B | $954.0M | $2.90B | $1.75B | $1.58B | $546.0M | $1.40B | $1.00B | $1.15B | $1.92B |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.54B | $7.57B | $6.67B | $7.08B | $7.77B | $7.92B | $6.96B | $7.80B |
| Growth (year over year) | +7.0% | +6.4% | −0.3% | +1.8% | +3.0% | +4.7% | +4.4% | +10.2% |
| Gross profit | $5.97B | $5.99B | $5.13B | $5.58B | $6.20B | $6.30B | $5.51B | $6.22B |
| Gross margin | 79.1% | 79.1% | 76.9% | 78.8% | 79.8% | 79.5% | 79.2% | 79.8% |
| Operating income | $888.0M | $2.45B | $2.24B | $2.47B | $3.33B | $1.98B | $2.59B | −$10.4B |
| Operating margin | 11.8% | 32.4% | 33.6% | 34.9% | 42.8% | 25.0% | 37.2% | −133.2% |
| Net income | $1.25B | $1.78B | $1.31B | $1.96B | $3.05B | $2.18B | $2.02B | −$10.5B |
| Net margin | 16.6% | 23.6% | 19.7% | 27.7% | 39.3% | 27.5% | 29.0% | −134.5% |
| EPS (diluted) | $1.00 | $1.43 | $1.04 | $1.56 | $2.43 | $1.75 | $1.61 | −$8.45 |
| Balance sheet | ||||||||
| Cash and equivalents | $5.04B | $9.99B | $7.93B | $5.14B | $7.33B | $7.56B | $7.63B | $3.18B |
| Total assets | $54.5B | $59.0B | $56.4B | $55.7B | $58.5B | $59.0B | $56.3B | $49.4B |
| Total liabilities | $36.1B | $39.7B | $37.4B | $36.1B | $37.1B | $36.4B | $32.8B | $37.6B |
| Long-term debt | $21.4B | $24.9B | $22.1B | $22.1B | $22.1B | $22.1B | $20.9B | $23.8B |
| Shareholders' equity | $18.5B | $19.3B | $19.2B | $19.7B | $21.5B | $22.7B | $23.5B | $11.8B |
| Cash flow | ||||||||
| Operating cash flow | $4.31B | $2.98B | $1.76B | $827.0M | $4.11B | $3.33B | $2.54B | $3.57B |
| Capital expenditure | $141.0M | $147.0M | $104.0M | $107.0M | $147.0M | $205.0M | $117.0M | $140.0M |
| Free cash flow | $4.17B | $2.83B | $1.65B | $720.0M | $3.96B | $3.12B | $2.43B | $3.43B |
| Dividends paid | $983.0M | $973.0M | $1.01B | $994.0M | $1.00B | $994.0M | $1.04B | $1.03B |
| Share buybacks | $300.0M | $350.0M | $730.0M | $527.0M | $435.0M | $230.0M | $419.0M | $355.0M |
From Gilead Sciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Gilead Sciences
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Source: Wikipedia — Gilead Sciences
- Headquarters
- Foster City, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- DXCM Dexcom
- ELV Elevance Health
- EW Edwards Lifesciences
- GEHC GE HealthCare
- HCA HCA Healthcare
- HSIC Henry Schein
- HUM Humana
- IDXX Idexx Laboratories